(Boursier.com) — Eurobio Scientific recorded a turnover of €130.1 million on its core business at the end of 2023.
COVID detection is now integrated into multiplex respiratory panels, and in particular influenza syndrome respiratory panels representing a total turnover of around 6 ME over the full year.
The group generated a turnover of €152.6 million in 2022. Excluding the exceptional turnover linked to COVID activity, 2023 growth therefore amounts to +39%.
On a comparable proforma basis, that is to say excluding scope effects linked to acquisitions and non-recurring items, growth remains dynamic in the core business, at +12%.
©2024 Boursier.com